For the first time in more than 50 years, the federal government has fundamentally changed how it classifies medical marijuana, and for millions of patients and researchers, this is a very big deal. Effective April 28, 2026, the Justice Department and the Drug Enforcement Administration officially moved FDA-approved cannabis products and state-licensed medical marijuana from Schedule I to Schedule III of the Controlled Substances Act. Schedule I — the most restrictive category, reserved for substances with “no accepted medical use” — is where marijuana has sat since 1970, alongside heroin. Moving to Schedule III, the same category as ketamine and certain anabolic steroids, is a landmark shift that recognizes what 40 U.S. states have already acknowledged for years: medical marijuana has genuine therapeutic value. For patients, the change could improve access and affordability, as medical cannabis businesses will no longer face a punishing tax rule that had effectively prohibited them from deducting standard business expenses, often pushing effective federal tax rates on those businesses as high as 70 to 80 percent.
For scientists, the rescheduling is equally significant. Schedule I status has long created enormous barriers to cannabis research, making it exceptionally difficult to study a substance tens of millions of Americans already use. Researchers studying everything from chronic pain to epilepsy to PTSD have faced federal restrictions that simply don’t apply to other substances under study. Those barriers will now ease meaningfully. A DEA administrative hearing beginning June 29, 2026, will consider whether the rescheduling extends to all marijuana — including recreational products. For now, the immediate and historic win belongs to the patients, doctors, and researchers who have long argued that science, not stigma, should drive federal drug policy.
